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Cardiovascular disease (CVD) is the leading cause of death in the U.S. and 
worldwide claiming 17.9 million deaths, representing 31% of all global 
deaths [1]
Figure:1 Source: CDC/NCHS, Health, United States, 2013, Table 20. Data 
from the National Vital Statistics System (NVSS).
• Aspirin is a widely prescribed antiplatelet medicine for the treatment and 
prevention of CVD. It is estimated that 48.7 million US adults are 
taking aspirin for prevention of cardiovascular disease (CVD). The 
majority (~73%) for primary prevention [2]. 
• The literature supports the role of low dose of aspirin in the primary 
prevention of CVD, recent studies have shown this topic to be 
controversial. Evidences unveil discrepancies between clinical guidelines 
for the use of low aspirin dosage towards primary prevention of CVD and 
the clinical pattern followed by patients [3.4].
Introduction
Table 1. Descriptive Statistics
Table 2. Multivariable Logistic Regression
Objective
Sample: NHANES 2013-2014, N=62,776
Data items: Age, Male, BMI, Smoking, Alcohol use, Admission to hospital,
cardiovascular diseases, Comorbidities
Statistical analyses:
1) descriptive statistics, including bivariate analysis used to identify
differences between the groups, and test the association between Aspirin
and Cardiovascular diseases, and between Aspirin and each of the
confounding variables: Age, Male, BMI, Smoking, Alcohol use,
Admission to hospital and other Comorbidities
2) a multivariate regression was used to test the relationship between aspirin
and cardiovascular disease while controlling for Age, Male, BMI,
Smoking, Alcohol use, Admission to hospital and other Comorbidities
Methods	and	Materials
• Primary and secondary prevention of CAD is reflected in the data showing 
an inverse correlation between age and CAD among those prescribed low 
dose aspirin. The youngest age group (40-49 years) may have the highest 
odds due to lower primary prevention of CAD in this age group. It  
suggests that low dose aspirin is used in response to existing CAD rather 
than as a primary prevention technique. Above 50 years, low dose aspirin is 
routinely used in primary prevention regardless of existing CAD.
• The non significant association between BMI and CAD is explained by the 
fact that BMI quantifies general adiposity. It can not give an accurate view 
regarding fat distribution in body. While fat distribution is an important 
determinant of CAD, BMI shouldn't be use a reliable indictor of CAD. 
Central obesity is important predictor for CAD prevalence, which can be 
measured using waist circumference. The American Heart Association 
(AHA) and National Heart, Lung, and Blood Institute (NHLBI) set the 
thresholds at ≥ 102 cm in men and ≥88 cm in women [6]
• The association between smoking and CAD occurs because smoking 
initiates atherogenesis through oxidation and endothelial scarring. In turn, 
subsequent endothelial dysfunction increases susceptibility of healthy 
vessels for atheroma formation. Smoking also increases the formation of 
proatherogenic lipids and increases blood pressure [7]
• The decrease in high-density lipoproteins (HDL), and the accumulation of 
proatherogenic lipids like triglycerides (TGs), trans fatty acids (Tans FA), 
and low density lipoproteins (LDL) will speed up atherogenesis. Induced 
inflammation, oxidation, and lipoperoxidation may differ depending on the 
severity of vascular scarring. Measuring these factors may help improve 
assessment when determining atherosclerosis progression. Specifically, 
measuring Trans FA accumulation maybe be a predictive factor of con-
current disease among CAD patients [8]. 
• Patients with COPD have a prominent systemic inflammatory response due 
to hyperactive immune systems., hence the positive association. C-reactive 
protein (CRP), is a known marker of systemic inflammation increases in 
stable and exacerbated conditions of COPD. These instigate a noxious 
environment for vessel integrity. studies confirm the role of CRP in CAD 
progression [9].
Study Limitations
• The data is representative of the U.S population across demographics and 
co-morbidities (e.g. CVD, DM, HTN, Asthma, Cancer, COPD). The data 
then has external validity.
• Since the study is cross-sectional, the data shows no causal association 
between CAD and low dose aspirin use. Only correlational data has been 
extrapolated. Additionally, aspirin use may have been misclassified, as some 
patients may have used OTC aspirin instead of the prescribed dose. 
• Stratifying the data by additional factors such as race, lifestyle, PVD and 
Rheumatic heart disease will increase the strength of the study
Conclusions
Using a nationally representative sample, this study sought to examine
impact of low dose of aspirin and coronary artery disease in order to
assess a plausible association between aspirin and a CAD.
Results
Descriptive Statistics:
• Among 62,776 participants (40 years or old), 4829 (7.7%) were taking low 
dose of aspirin (mean age = 64.47 ± 10.54 years).
• Male have higher proportion in low dose of aspirin usage (51.4%) than 
female. There were an increase in usage of ASA in more than 70 years of 
age group (34.6%), compare to other age groups.  
• People with 25.1-40 KG/M2 of BMI (71.1%), smoker (52.8%) , alcoholic 
(75.2%) with hospital admission for at least 0-2 times (45%) have higher 
portion in ASA use.
• More than half of people, who were using ASA had high blood pressure 
(64.7%) and hyperlipidemia (67.5%). Almost half people seem to have 
arthritis (50.4%) as comorbidity. There were also some other comorbidities 
associated with ASA usage, like diabetes (26.3%), diagnosis of cancer 
(24.5%), asthma (16.3) and COPD (10.5%).
• A crosstabulation analysis carried out to test association between low dose 
of aspirin and coronary artery disease. A significant association found 
between χ2 (1) = 692.463, p<.001, which suggest significant association 
between low dose of aspirin usage and coronary artery disease.
Logistic Regression:
Unadjusted model (χ2 (1) =829.375, p <.001):
Unadjusted model explained 17.6% (Nagelkerke R2) of the variation of 
having coronary artery disease, and correctly classified 94.5% of cases. 
People who take low dose of aspirin are 11.7 times more likely to have had 
coronary artery disease than those who don’t.  
Adjusted model (χ2 (15) =2422.801, p <.001):
• Adjusted model explained 48.4% (Nagelkereke R2) of the variation, and
correctly classified 96.1% of cases.
• Those prescribed low dose aspirin are more likely to have CAD than
patients who are not. As age increases among those prescribed aspirin, the
odds of having CAD deceases.
• BMI and alcohol use exhibit no significant association with CAD. In
contrast, those who have smoked at least 100 cigarettes in life are 1.3 times
more likely to have CAD than those who have not.
• Patients who were hospitalized had higher odds of having CAD than non-
hospitalized patients. Among those hospitalized, patients hospitalized 0-2
times had a higher odds of having CAD than those who were hospitalized 3
or more times.
• Congestive heart failure, angina pectoris, myocardial infarction, and COPD
have a significant positive association with CAD. These patients have a
higher odds of having CAD than patients without these diseases. Stroke
diagnosis has no significant association with CAD.
• Patients with high cholesterol and high blood pressure have a higher odds of
having CAD than patients who do not. Diagnoses of diabetes and COPD
also increase the odds of CAD
• Patients with asthma and arthritis have a lower odds of having CAD than













Age (Mean/ Standard deviation) N=62,776 64.47 (10.54) 54.64 (10.90) 51.828 0.112 
Age (%)       2280.938 <0.001 
40-49        29.1 8.8 39.1     
50-59 28.8 23.8 31.3     
60-69 22.7 32.9 17.7     
More than 70 19.3 34.6 11.8     
Male (%) 47.3 51.4 45.2 49.813 <0.001 
BMI (Kg/m2) (%)       102.144 <0.001 
≤25 26 20.8 28.6     
25.1-40 66.6 71.1 64.4     
40.1 ≥ 7.4 8.1 7.0     
Smoking (%) 46.7 52.8 43.7 107.687 <0.001 
Alcohol use (%)                                       77 75.2  77.9 12.501 <0.001 
Admission to hospital (%)       426.352 <0.001 
0-2 times  57 45 63     
3-5 times 29.1 37.3 25.1     
≥6 times 13.9 17.7 12     
ASA indication (%)           
Myocardial Infarction 5.1 11.9 1.7 692.463 <0.001 
 Angina Pactoris 3.1 7.5 1 443.088 <0.001 
Coronary Artery Disease 5.5 13.7 1.4 947.124 <0.001 
Congestive Heart Failure 3.9 7.8 1.9 299.552 <0.001 
Stroke 4.4 8.9 2.2 345.786 <0.001 
Comorbidities (%)      
High blood pressure 46.5 64.7 37.6 952.229 <0.001 
Hyperlipidemia 47.9 67.5 38.2 1102.180 <0.001 
Diabetes 14.7 26.3 9 828.370 <0.001 
cancer 15.8 24.5 11.5 408.191 <0.001 
Asthma 14.1 16.3 13.0 29.213 <0.001 
Arthritis 38.2 50.4 32.1 454.201 <0.001 
COPD 5.1 10.5 2.4 441.200 <0.001 
	
Figure:2. Cardiovascular Effects of Exposure to Cigarette Smoke and 
Electronic Cigarettes. [5]
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